Interactions on record — worth a quick check against your medications. Based on 3 of 4 ingredients. Check your meds →
Dietary supplement

Estro One Ingredients & Drug Interactions

by NutraOne

Capsule Category: Other Combinations
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Estro One is a dietary supplement by NutraOne with 4 active ingredients. Its ingredients are commonly taken for estrogen/hormone balance, acne and hormonal skin issues, prostate health support.Based on those ingredients, 451 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Indole-3-Carbinol, 3,3'-Diindolylmethane, Agaricus bisporus extract. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Estro One by NutraOne

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 4 active ingredients.
  • “Proprietary Blend” is a proprietary blend — the label gives one combined amount (620 mg) without saying how much of each component you get.

Estro One contains 4 active ingredients. The first three — 3,3'-diindolylmethane, indole-3-carbinol, and agaricus bisporus mushroom extract — are compounds extracted from cruciferous vegetables and mushrooms, historically used in women's health formulas.

The fourth ingredient, 5,7-dihydroxy-4'-methoxyflavone, is listed but we hold no detailed information on it. The product also contains inactive ingredients (maltodextrin, gelatin, titanium dioxide, FD&C Blue #1, magnesium stearate, and silicon dioxide) as capsule binders and fillers.

Does it work?

Not established
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Not established

The graded evidence we hold for these ingredients covers different conditions than the ones this product is marketed for, so there's no established rating for its stated use.

Why this rating?
  • The label markets this product for: balance hormones and estrogen suppression.
  • We looked for evidence on: Premenstrual syndrome (PMS), Benign prostatic hyperplasia (BPH), Breast cancer, Prostate cancer, Cervical dysplasia, Uterine cancer — and 4 related terms.
  • The closest evidence on file: Indole-3-carbinol is rated "Insufficient Reliable Evidence To Rate" for Breast cancer (Natural Medicines).
  • Also on file: Indole-3-carbinol is rated "Insufficient Reliable Evidence To Rate" for Cervical dysplasia, Ovarian cancer.
  • Also on file: Diindolylmethane is rated "Insufficient Reliable Evidence To Rate" for Benign prostatic hyperplasia (BPH), Breast cancer, Cervical dysplasia, Premenstrual syndrome (PMS).

The evidence for what this product can do isn't yet established in the data we hold. Both diindolylmethane and indole-3-carbinol have been studied for breast cancer, colorectal cancer, cervical dysplasia, and related conditions — but so far the research is insufficient to rate whether they're effective for any of these.

The agaricus mushroom extract shows the same pattern across allergic rhinitis, osteoporosis, cancer, heart disease, and chemotherapy side effects. That doesn't mean the product doesn't work; it means the clinical evidence isn't conclusive enough yet to say.

The evidence, ingredient by ingredient Diindolylmethane Indole-3-carbinol Agaricus Mushroom

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 3 of the 3 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 3 of 3.
  • General safety write-ups exist for 3 of 3.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Both diindolylmethane and indole-3-carbinol are generally well tolerated in short-term studies, but long-term safety isn't well established. The most common side effects are gastrointestinal — diarrhea, gas, nausea, and headache.

At higher doses, indole-3-carbinol has been linked to unsteadiness and tremor in a small number of people; these resolved when doses were lowered. Agaricus mushroom is generally well tolerated as a food, but supplement safety isn't well documented — rare cases of severe liver damage have been reported, mostly in people with cancer receiving chemotherapy.

For pregnancy, diindolylmethane is rated likely safe. Indole-3-carbinol has no pregnancy data on file — there isn't enough information to know either way.

Agaricus mushroom should be avoided in pregnancy due to insufficient safety data. For breastfeeding, the safety data advises against both diindolylmethane and agaricus mushroom, and indole-3-carbinol data is insufficient — talk with your doctor or pharmacist before using this product if you're nursing.

Side effects, ingredient by ingredient Diindolylmethane Indole-3-carbinol Agaricus Mushroom

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 3 of the 3 matched ingredients can interact with medications — Indole-3-carbinol, Diindolylmethane, Agaricus Mushroom.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; diabetes medications.
  • For scale: 451 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before taking this product, double-check with your doctor or pharmacist if you take estrogens (including birth control or hormone replacement therapy), blood thinners or antiplatelet drugs like warfarin or clopidogrel, diabetes medications, or water pills (diuretics). No interactions are documented in our data for 5,7-dihydroxy-4'-methoxyflavone, but we hold no detailed information on that ingredient.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with no established evidence rating for its marketed use. Moderate medication interactions have been identified, and safety information is well characterized.

Estro One is designed for women's hormonal health but carries notable interactions with estrogens, blood thinners, diabetes drugs, and several other medication types. If you take any prescription medication — especially hormone therapy — check your exact drugs with your doctor or pharmacist before starting.

The long-term safety profile isn't well studied, and evidence for its effectiveness in any condition isn't yet conclusive.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 3 of 4 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Feb 23, 2022.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Estro One, straight from the product label.

Brand NutraOne
Net contents 60 Capsule(s)
Market status On market
Date entered into DSLD Feb 23, 2022
DSLD ID 265990
Product type Other Combinations
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years)
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Estro One by NutraOne, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
2 Capsule(s)
Maximum serving Sizes:
2 Capsule(s)
Servings per container
30
IngredientAmount% DV
Proprietary Blend620 mg--
3,3'-Diindolylmethane0 NP--
Indole-3-Carbinol0 NP--
Agaricus bisporus extract0 NP--
5,7-Dihydroxy-4'-methoxyflavone0 NP--

Other ingredients: Maltodextrin, Gelatin, Titanium Dioxide, FD&C Blue #1, Magnesium Stearate, Silicon Dioxide

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Seals/Symbols

cGMP Certified Good Manufacturing Practice Made in the USA with Pride

Formulation

Cut water Balance hormones Increase density Estrogen suppressor

Shred fat Increase density Cut water

FDA Statement of Identity

Dietary Supplement

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

See for yourself

Estro One by NutraOne label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Estro One by NutraOne

These are the 4 active ingredients this product is made of. Select any to open its full monograph.

Serving size2 Capsule(s) Dosage formCapsule Servings per container30 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Proprietary Blend

620 mg per serving

Other (inactive) ingredients: Maltodextrin, Gelatin, Titanium Dioxide, FD&C Blue #1, Magnesium Stearate, Silicon Dioxide. These complete the product’s ingredient list but are not active constituents.

Interaction report

Estro One by NutraOne Drug Interactions

Want to check YOUR meds against Estro One?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
451Drugs
451 Moderate

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in Estro One with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Indole-3-Carbinol3 drug types · 294 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, indole-3-carbinol might increase the risk of bleeding when used with antiplatelet or anticoagulant drugs.
In vitro research shows that indole-3-carbinol inhibits platelet aggregation.

Likelihood Possible Evidence D
Cytochrome P450 1A2 (Cyp1A2) Substrates

Theoretically, indole-3-carbinol might increase the metabolism of CYP1A2 substrates and lower serum concentrations.
Animal research shows that indole-3-carbinol induces CYP1A2 enzymes.

Likelihood Possible Evidence D
Estrogens

Indole-3-carbinol might interfere with the effects of estrogen therapy.
Preliminary clinical and in vitro evidence shows that indole-3-carbinol has antiestrogenic activity.

Likelihood Possible Evidence D

3,3'-Diindolylmethane3 drug types · 269 drugs

Diuretic Drugs

Theoretically, diindolylmethane might increase the risk of hyponatremia if used with sodium-depleting diuretics.
Large doses of diindolylmethane (600 mg daily) have been associated with two cases of asymptomatic hyponatremia in clinical research.

Likelihood Possible Evidence B
Estrogens

Theoretically, diindolylmethane might increase or decrease the effects of estrogens.
Diindolylmethane might have mild estrogenic or antiestrogenic effects. Theoretically, large amounts of diindolylmethane might interfere with hormone replacement therapy.

Likelihood Possible Evidence D
Cytochrome P450 1A2 (Cyp1A2) Substrates

Theoretically, diindolylmethane might lower serum levels of CYP1A2 substrates.
In vitro evidence suggests that diindolylmethane can induce CYP1A2. Theoretically, it might increase metabolism of CYP1A2 substrates and lower serum concentrations. This interaction has not been reported in humans.

Likelihood Unlikely Evidence D

Agaricus bisporus extract1 drug type · 86 drugs

Antidiabetes Drugs

Theoretically, taking agaricus mushroom with antidiabetes drugs might increase the risk of hypoglycemia.
In one clinical study in patients with type 2 diabetes who are stabilized on conventional oral hypoglycemic agents, 3 of 29 patients taking an agaricus mushroom extract 500 mg three times daily for 12 weeks reported hypoglycemia, compared to one of 29 patients in the placebo group.

Likelihood Possible Evidence D
The maker

Brand information

Manufacturer and brand details for Estro One, from the product label.

NutraOne

See all NutraOne products
Name
NutraOne Nutrition
Pharmacist Counseling Corner

Estro One by NutraOne: Common Questions

Does Estro One by NutraOne interact with any medications?
Yes. Based on its ingredients, Estro One has a known interaction with 451 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Estro One contains 4 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I take this if I'm on hormone replacement therapy?
Not without checking with your doctor first. Both main ingredients in this product may interfere with estrogen effects — they could make it stronger, weaker, or unpredictable. Your doctor needs to know you're considering it.
What are the most common side effects?
Diarrhea, nausea, gas, and headache are the most often reported. Indole-3-carbinol at higher doses has also caused unsteadiness and tremor in some people, though these went away when the dose was cut.
Is it safe to take while pregnant or breastfeeding?
Diindolylmethane is rated likely safe in pregnancy, but indole-3-carbinol and agaricus mushroom don't have enough safety data — talk with your doctor or pharmacist. If you're breastfeeding, the data advises against diindolylmethane and agaricus mushroom, and indole-3-carbinol data is insufficient.
Does this product actually work for anything?
The ingredients have been studied for breast cancer, colorectal cancer, and cervical dysplasia, but the evidence so far isn't strong enough to say they're effective. More research is needed.
I'm diabetic — can I use this?
The agaricus mushroom in this product may lower blood sugar, which could raise the risk of hypoglycemia if you're on diabetes medication. Check with your doctor or pharmacist before taking it.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Estro One is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Estro One label
Sources

Sources & How We Checked

Estro One's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 28 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Diindolylmethane 14 references
  1. Natl Inst Health, Natl Inst Environmental Health Sci. Indole-3-carbinol. Available at: http://ntp-server.niehs.nih.gov.
  2. Balk JL. Indole-3-carbinol for cancer prevention. Altern Med Alert 2000; 3:105-7.
  3. Riby JE, Chang GHF, Firestone GL, Bjeldanes LF. Ligand-independent activation of estrogen receptor function by 3,3'-diindolylmethane in human breast cancer cells. Biochem Pharmacol 2000;60:167-77. PubMed
  4. Lake BG, Tredger JM, Renwick AB, et al. 3'3-diindolylmethane induces CYP1A2 in cultured precision-cut human liver slices. Xenobiotica 1998;28:803-11. PubMed
  5. Dalessandri, K. M., Firestone, G. L., Fitch, M. D., Bradlow, H. L., and Bjeldanes, L. F. Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Canc PubMed
  6. Reed, G. A., Arneson, D. W., Putnam, W. C., Smith, H. J., Gray, J. C., Sullivan, D. K., Mayo, M. S., Crowell, J. A., and Hurwitz, A. Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3'-diindolylmetha
  7. Reed, G. A., Sunega, J. M., Sullivan, D. K., Gray, J. C., Mayo, M. S., Crowell, J. A., and Hurwitz, A. Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3'-diindolylmethane in healthy subjects. Cancer Epidemiol.Biomarkers Prev. 2008; PubMed
  8. Del Priore G., Gudipudi, D. K., Montemarano, N., Restivo, A. M., Malanowska-Stega, J., and Arslan, A. A. Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia. Gynecol.Oncol. 2010;116(3):464-467. PubMed
  9. Heath, E. I., Heilbrun, L. K., Li, J., Vaishampayan, U., Harper, F., Pemberton, P., and Sarkar, F. H. A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. Am.J.Transl.R
  10. Jellinck, P. H., Forkert, P. G., Riddick, D. S., Okey, A. B., Michnovicz, J. J., and Bradlow, H. L. Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem.Pharmacol. 3-9-1993;45(5):1129-1136. PubMed
  11. Bui PV, Moualla M, Upson DJ. A Possible Association of Diindolylmethane with Pulmonary Embolism and Deep Venous Thrombosis. Case Rep Med. 2016;2016:7527098. PubMed
  12. Castañon A, Tristram A, Mesher D, Powell N, Beer H, Ashman S, Rieck G, Fielder H, Fiander A, Sasieni P. Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial. Br J Cancer. 20 PubMed
  13. Le TM, Sanders CJ, van de Corput L, van Erpecum KJ, Röckmann H. Drug rash with eosinophilia and systemic symptoms caused by the dietary supplement diindolylmethane. J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):175-6. PubMed
  14. Pence ST, Mehta K, Crum-Bailey J. The Serious Side of Supplements: An Ischemic Stroke in a Healthy 38-year-old Female. Mil Med 2022. PubMed

See these in context on the Diindolylmethane monograph →

Indole-3-carbinol 9 references
  1. Rosen CA, Woodson GE, Thompson JW, et al. Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1998;118:810-5. PubMed
  2. Bell MC, Crowley-Nowick P, Bradlow HL, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 2000;78:123-9. PubMed
  3. He YH, Friesen MD, Ruch RJ, Schut HA. Indole-3-carbinol as a chemopreventive agent in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) carcinogenesis: inhibition of PhIP-DNA adduct formation, acceleration of PhIP metabolism, and induction of cytoch
  4. Kim, Y. S. and Milner, J. A. Targets for indole-3-carbinol in cancer prevention. J.Nutr.Biochem. 2005;16(2):65-73. PubMed
  5. Anon. Indole-3-carbinol. Monograph. Alternative Medicine Review 2005;10(4):337-42.
  6. McAlindon TE, Gulin J, Chen T, et al. Indole-3-carbinol in women with SLE: effect on estrogen metabolism and disease activity. Lupus 2001;10:779-83. PubMed
  7. Reed GA, Peterson KS, Smith HJ, et al. A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol Biomarkers Prev 2005;14:1953-60. PubMed
  8. Bradlow HL, Michnovicz JJ, Halper M, et al. Long-term responses of women to indole-3-carbinol or a high fiber diet. Cancer Epidemiol Biomarkers Prev 1994;3:591-5.
  9. Paliwal P, Chauhan G, Gautam D, Dash D, Patne SCU, Krishnamurthy S. Indole-3-carbinol improves neurobehavioral symptoms in a cerebral ischemic stroke model. Naunyn Schmiedebergs Arch Pharmacol. 2018;391(6):613-625. PubMed

See these in context on the Indole-3-carbinol monograph →

Agaricus Mushroom 5 references
  1. Hsu CH, Liao YL, Lin SC, et al. The mushroom Agaricus Blazei Murill in combination with metformin and gliclazide improves insulin resistance in type 2 diabetes: a randomized, double-blinded, and placebo-controlled clinical trial. J Altern Complement Med 2
  2. Mukai H, Watanabe T, Ando M, Katsumata N. An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients. Jpn J Clin Oncol 2006;36:808-10. PubMed
  3. Ohno S, Sumiyoshi Y, Hashine K, et al. Phase I clinical study of the dietary supplement, Agaricus blazei Murill, in cancer patients in remission. Evid Based Complement Alternat Med 2011, doi 10.1155/2011/192381.
  4. Suehiro M, Katoh N, Kishimoto S. Chelitis due to Agaricus blazei Murill mushroom extract. Contact Dermatitis 2007;56(5):293-4.
  5. Iwai N, Okuda T, Sawada R, et al. Interstitial lung disease associated with Agaricus blazei Murill in a patient with pancreatic ductal adenocarcinoma receiving gemcitabine-based therapy. Case Rep Gastroenterol 2022;16(1):229-234.

See these in context on the Agaricus Mushroom monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring